Sheng Yan

506 total citations
12 papers, 354 citations indexed

About

Sheng Yan is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Sheng Yan has authored 12 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 3 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Sheng Yan's work include Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Sheng Yan is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Sheng Yan collaborates with scholars based in China, Japan and United States. Sheng Yan's co-authors include Danni Zhong, Chaoyi Liu, Yuchen Qi, Shihong Chen, Min Zhou, Shumei Wei, Ming Jin, Qiyi Zhang, Xingyu Liu and Lufei Zhang and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and The FASEB Journal.

In The Last Decade

Sheng Yan

11 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheng Yan China 8 141 92 64 53 45 12 354
Zhengchen Jiang China 9 135 1.0× 64 0.7× 63 1.0× 49 0.9× 43 1.0× 30 318
Sheng‐Mao Wu Taiwan 11 165 1.2× 61 0.7× 62 1.0× 38 0.7× 33 0.7× 21 421
Noha A. Amin Egypt 12 267 1.9× 57 0.6× 51 0.8× 37 0.7× 46 1.0× 13 472
Lifang Wu China 14 189 1.3× 56 0.6× 42 0.7× 108 2.0× 29 0.6× 23 424
Xiufeng Zheng China 10 135 1.0× 47 0.5× 111 1.7× 39 0.7× 98 2.2× 24 435
Konrad Zaręba Poland 11 161 1.1× 84 0.9× 131 2.0× 63 1.2× 66 1.5× 46 436
Dongke Xu China 8 191 1.4× 61 0.7× 66 1.0× 89 1.7× 79 1.8× 9 352
Shiqiang Shen China 12 144 1.0× 86 0.9× 80 1.3× 78 1.5× 34 0.8× 22 453
Mengli Yu China 12 163 1.2× 72 0.8× 30 0.5× 40 0.8× 30 0.7× 23 473
Shilei Wen China 11 221 1.6× 62 0.7× 41 0.6× 81 1.5× 21 0.5× 26 427

Countries citing papers authored by Sheng Yan

Since Specialization
Citations

This map shows the geographic impact of Sheng Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng Yan more than expected).

Fields of papers citing papers by Sheng Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng Yan. The network helps show where Sheng Yan may publish in the future.

Co-authorship network of co-authors of Sheng Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Sheng Yan. A scholar is included among the top collaborators of Sheng Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng Yan. Sheng Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Shen, Lin, Huaxin Duan, Takamichi Kuwahara, et al.. (2025). Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study. Japanese Journal of Clinical Oncology. 55(11). 1229–1236. 1 indexed citations
2.
3.
Furuse, Junji, Bo Jiang, Takamichi Kuwahara, et al.. (2024). Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).. Journal of Clinical Oncology. 42(3_suppl). 471–471. 9 indexed citations
4.
Xu, Shaoyan, Zedong Jiang, Guogang Li, et al.. (2023). In vivo total or partial hepatectomy followed by ex vivo liver resection and autotransplantation for malignant tumors: a single center experience. Frontiers in Oncology. 13. 1214451–1214451. 1 indexed citations
5.
Zhong, Danni, Yuchen Qi, Chaoyi Liu, et al.. (2023). Bioinspired pH-Responsive Microalgal Hydrogels for Oral Insulin Delivery with Both Hypoglycemic and Insulin Sensitizing Effects. ACS Nano. 17(14). 14161–14175. 61 indexed citations
6.
Zhang, Qiyi, Xingyu Liu, Shumei Wei, et al.. (2021). Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Frontiers in Oncology. 11. 751391–751391. 55 indexed citations
7.
Xu, Chang, Man Zhang, Guangping Zhang, Sheng Yan, & Weiqi Yan. (2021). Hydrogen Sulfide Improves Functional Recovery in Rat Traumatic Spinal Cord Injury Model by Inducing Nuclear Translocation of NF-E2-Related Factor 2. Biological and Pharmaceutical Bulletin. 44(8). 1093–1100. 15 indexed citations
8.
9.
Wan, Xingyong, Xudong Zhu, Hu Wang, et al.. (2020). PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10‐mediated anti‐inflammatory response. The FASEB Journal. 34(8). 10751–10761. 26 indexed citations
10.
Yan, Sheng, et al.. (2019). Relationship between behavioral diversity and musk secretion of captive forest musk deer. 36(2). 343–348. 2 indexed citations
11.
Xu, Jun, et al.. (2016). Surgical management of isolated retroperitoneal Castleman's disease: A case report. Oncology Letters. 11(3). 2123–2126. 8 indexed citations
12.
Yan, Sheng. (2015). Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: An update. World Journal of Gastroenterology. 21(12). 3492–3492. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengchen Jiang Breakdown of academic impact, for papers by Sheng‐Mao Wu Breakdown of academic impact, for papers by Noha A. Amin Breakdown of academic impact, for papers by Lifang Wu Breakdown of academic impact, for papers by Xiufeng Zheng Breakdown of academic impact, for papers by Konrad Zaręba Breakdown of academic impact, for papers by Dongke Xu Breakdown of academic impact, for papers by Shiqiang Shen Breakdown of academic impact, for papers by Mengli Yu Breakdown of academic impact, for papers by Shilei Wen
Rankless by CCL
2026